Proton therapy reduces radiation to nontargeted tissues, but for men with localized prostate cancer that may not translate to better outcomes, according to early results from the large prospective ...

In a randomized trial of men with intermediate-risk prostate cancer, stereotactic body radiotherapy (SBRT) improved bowel-related quality of life vs moderately hypofractionated intensity-modulated ...

SBRT is not superior to IMRT for DFS at 3 years, but it is safe and might permit better bowel quality of life. In men with favorable intermediate-risk prostate cancer, modest-dose stereotactic body ...

About the Study: In this randomized clinical trial of 698 patients with localized intermediate-risk prostate cancer, stereotactic body radiotherapy was not superior to moderately hypofractionated IMRT ...